Stay updated with breaking news from Keith Blundy. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
PharmEnable, a drug discovery company focused on chemical novelty, diversity and complexity, announces it has closed a Pre-Series A investment round of $7.5M to develop the next generation of small molecule drugs against disease areas of high clinical need. The funding round was led by MP Healthcare Venture ...
FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!
STORM to deliver small molecule ADAR1 clinical candidate compounds discovered using its proprietary RNA modifying enzyme drug discovery platform ALAMEDA, Calif. and CAMBRIDGE, England,
STORM to deliver small molecule ADAR1 clinical candidate compounds discovered using its proprietary RNA modifying enzyme drug discovery platform - Exelixis, Inc. (Nasdaq: EXEL) and STORM Therapeutics